SAN FRANCISCO, February 24, 2014 – The law firm of Gibbs Law Group LLP is investigating claims on behalf of testosterone supplement users that the hormone replacement therapy may be linked to an increased risk of stroke, heart attack, or other serious cardiovascular events.
The investigation comes in the wake of a Drug Safety Communication issued by the Food and Drug Administration (FDA) on January 31, 2014, which states the FDA has decided to reassess the safety issue following the publication of two separate studies that report increased cardiovascular events in men using TRT products. This increase is significant: a 3-fold increased risk for heart attack in men over 65, and double the risk of heart attack in men under 65 with prior heart disease. Still other studies report links between testosterone prescriptions and increased risk of stroke, pulmonary embolism, and death.
“Patients and their doctors need to know how testosterone, often prescribed as a lifestyle drug, could potentially affect patients’ lives when decreased testosterone is a natural part of aging. Drug manufacturers have a responsibility to provide adequate warnings about the potential health risks involved in increasing testosterone,” said Phyra McCandless, MPH, a personal injury attorney at Gibbs Law Group.
Testosterone supplements come in injection, pill, patch, and gel forms, and are approved by the FDA to treat symptoms of low testosterone, such as decreased sexual performance, low energy, loss of muscle, decreased strength, moodiness, and weight gain. Annual prescriptions for Low T supplements such as AndroGel, Axiron, Testopel, and Depo-testosterone rose more than five-fold from 2000 to 2011, reaching a total of 5.3 million prescriptions.
Consumers who have experienced serious cardiovascular events, such as heart attack or stroke, are encouraged to contact Gibbs Law Group’ testosterone lawyers to learn more about the investigation and explore their potential claims for monetary compensation.
Gibbs Law Group LLP has been distinguished by the U.S. News & World Report as a Tier-1 law firm for plaintiffs’ mass tort and class action litigation. In addition to representing people injured after taking low testosterone supplements, Gibbs Law Group represents plaintiffs involving Fresenius dialysate products GranuFlo and Naturalyte; Yaz, Yasmin, and Ocella birth control pills; the diabetes drug Actos; transvaginal mesh implants; Eon spinal cord stimulators; the DaVinci surgical robot; the Mirena IUD; and the blood-thinner Pradaxa.